Levofloxacin versus ceftriaxone plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring hospitalization
Consecutive adult patients admitted to the hospital with community-acquired pneumonia from January 2000 to September 2003 were included in this prospective observational cohort study. A total of 459 patients, 259 treated with levofloxacin in single drug therapy at a dose of 500 mg once a day and 209...
Gespeichert in:
| Veröffentlicht in: | International journal of antimicrobial agents 2005, Vol.25 (1), p.75-83 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 83 |
|---|---|
| container_issue | 1 |
| container_start_page | 75 |
| container_title | International journal of antimicrobial agents |
| container_volume | 25 |
| creator | Querol-Ribelles, José Manuel Tenías, José María Querol-Borrás, José Manuel Labrador, Teodoro Nieto, Angel González-Granda, Damiana Martínez, Isidoro |
| description | Consecutive adult patients admitted to the hospital with community-acquired pneumonia from January 2000 to September 2003 were included in this prospective observational cohort study. A total of 459 patients, 259 treated with levofloxacin in single drug therapy at a dose of 500
mg once a day and 209 with the combination of ceftriaxone plus clarithromycin at a dose of 2
g once a day and 500
mg every 12
h, respectively, were included. The hospital admission decision was made using a clinical guideline based on the Pneumonia Severity Index (PSI). Fifteen (6%) patients died in the group treated with levofloxacin in single drug therapy and 25 (12%) in the group treated with ceftriaxone plus clarithromycin (
P = 0.024). The mortality differences between both treatment groups, adjusted by the PSI score, show an OR of 0.39 (95% CI 0.17–0.87). There were no statistically significant differences between the duration of treatments or hospital stay. These data suggest that levofloxacin as single drug therapy is more effective than the combination of ceftriaxone plus clarithromycin in the treatment of moderate to severe pneumonia that requires hospitalization. |
| doi_str_mv | 10.1016/j.ijantimicag.2004.07.013 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67349476</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0924857904003061</els_id><sourcerecordid>67349476</sourcerecordid><originalsourceid>FETCH-LOGICAL-c436t-eabd2467f0c490a13ee90ef4fceb96af76f7bcc25d2b2d8cad182561dab1ea83</originalsourceid><addsrcrecordid>eNqN0c2KFDEQB_BGFHdcfQWJB711m_RH0jnK4BcMeNl7qE5XdjJ0J7NJetzxEXxq08zAelMIBIpfVUL9i-IdoxWjjH88VPYALtnZarivakrbioqKsuZZsWG9qEshWfO82FBZt2XfCXlTvIrxQCnrmrZ7Wdywjte0b-im-L3DkzeTfwRtHTlhiEskGk0KFh69Q3Kc1sIEwaZ98PN5ZfmkPZIUENKMLhFvCIzLlCL5mRnRfp4XZ9O5BP2w2IAjOTpcZu8skIBrybp7svfxaBNM9hck693r4oWBKeKb631b3H35fLf9Vu5-fP2-_bQrddvwVCIMY91yYahuJQXWIEqKpjUaB8nBCG7EoHXdjfVQj72GkfV1x9kIA0Pom9viw2XsMfiHBWNSs40apwkc-iUqLppWtoL_EzIhZJcnZygvUAcfY0CjjsHOEM6KUbUGpg7qr8DUGpiiQuXAcu_b6yPLMOP41HlNKIP3VwBRw2QCOG3jk-ON6CUV2W0vDvPqThaDitqi0zjm_eukRm__4zt_AHSUwH0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17795256</pqid></control><display><type>article</type><title>Levofloxacin versus ceftriaxone plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring hospitalization</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Querol-Ribelles, José Manuel ; Tenías, José María ; Querol-Borrás, José Manuel ; Labrador, Teodoro ; Nieto, Angel ; González-Granda, Damiana ; Martínez, Isidoro</creator><creatorcontrib>Querol-Ribelles, José Manuel ; Tenías, José María ; Querol-Borrás, José Manuel ; Labrador, Teodoro ; Nieto, Angel ; González-Granda, Damiana ; Martínez, Isidoro</creatorcontrib><description>Consecutive adult patients admitted to the hospital with community-acquired pneumonia from January 2000 to September 2003 were included in this prospective observational cohort study. A total of 459 patients, 259 treated with levofloxacin in single drug therapy at a dose of 500
mg once a day and 209 with the combination of ceftriaxone plus clarithromycin at a dose of 2
g once a day and 500
mg every 12
h, respectively, were included. The hospital admission decision was made using a clinical guideline based on the Pneumonia Severity Index (PSI). Fifteen (6%) patients died in the group treated with levofloxacin in single drug therapy and 25 (12%) in the group treated with ceftriaxone plus clarithromycin (
P = 0.024). The mortality differences between both treatment groups, adjusted by the PSI score, show an OR of 0.39 (95% CI 0.17–0.87). There were no statistically significant differences between the duration of treatments or hospital stay. These data suggest that levofloxacin as single drug therapy is more effective than the combination of ceftriaxone plus clarithromycin in the treatment of moderate to severe pneumonia that requires hospitalization.</description><identifier>ISSN: 0924-8579</identifier><identifier>EISSN: 1872-7913</identifier><identifier>DOI: 10.1016/j.ijantimicag.2004.07.013</identifier><identifier>PMID: 15620830</identifier><language>eng</language><publisher>London: Elsevier B.V</publisher><subject>Aged ; Anti-Bacterial Agents - administration & dosage ; Anti-Bacterial Agents - therapeutic use ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Biological and medical sciences ; Ceftriaxone ; Ceftriaxone - administration & dosage ; Ceftriaxone - therapeutic use ; Clarithromycin ; Clarithromycin - administration & dosage ; Clarithromycin - therapeutic use ; Cohort Studies ; Community-Acquired Infections - drug therapy ; Community-Acquired Infections - microbiology ; Community-Acquired Infections - mortality ; Community-acquired pneumonia ; Drug Therapy, Combination ; Female ; Hospitalization ; Humans ; Levofloxacin ; Male ; Medical sciences ; Mortality ; Ofloxacin - administration & dosage ; Ofloxacin - therapeutic use ; Pharmacology. Drug treatments ; Pneumonia, Bacterial - drug therapy ; Pneumonia, Bacterial - microbiology ; Pneumonia, Bacterial - mortality ; Prospective Studies ; Treatment Outcome</subject><ispartof>International journal of antimicrobial agents, 2005, Vol.25 (1), p.75-83</ispartof><rights>2004 Elsevier B.V. and the International Society of Chemotherapy</rights><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c436t-eabd2467f0c490a13ee90ef4fceb96af76f7bcc25d2b2d8cad182561dab1ea83</citedby><cites>FETCH-LOGICAL-c436t-eabd2467f0c490a13ee90ef4fceb96af76f7bcc25d2b2d8cad182561dab1ea83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijantimicag.2004.07.013$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,4024,27923,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16378907$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15620830$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Querol-Ribelles, José Manuel</creatorcontrib><creatorcontrib>Tenías, José María</creatorcontrib><creatorcontrib>Querol-Borrás, José Manuel</creatorcontrib><creatorcontrib>Labrador, Teodoro</creatorcontrib><creatorcontrib>Nieto, Angel</creatorcontrib><creatorcontrib>González-Granda, Damiana</creatorcontrib><creatorcontrib>Martínez, Isidoro</creatorcontrib><title>Levofloxacin versus ceftriaxone plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring hospitalization</title><title>International journal of antimicrobial agents</title><addtitle>Int J Antimicrob Agents</addtitle><description>Consecutive adult patients admitted to the hospital with community-acquired pneumonia from January 2000 to September 2003 were included in this prospective observational cohort study. A total of 459 patients, 259 treated with levofloxacin in single drug therapy at a dose of 500
mg once a day and 209 with the combination of ceftriaxone plus clarithromycin at a dose of 2
g once a day and 500
mg every 12
h, respectively, were included. The hospital admission decision was made using a clinical guideline based on the Pneumonia Severity Index (PSI). Fifteen (6%) patients died in the group treated with levofloxacin in single drug therapy and 25 (12%) in the group treated with ceftriaxone plus clarithromycin (
P = 0.024). The mortality differences between both treatment groups, adjusted by the PSI score, show an OR of 0.39 (95% CI 0.17–0.87). There were no statistically significant differences between the duration of treatments or hospital stay. These data suggest that levofloxacin as single drug therapy is more effective than the combination of ceftriaxone plus clarithromycin in the treatment of moderate to severe pneumonia that requires hospitalization.</description><subject>Aged</subject><subject>Anti-Bacterial Agents - administration & dosage</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Biological and medical sciences</subject><subject>Ceftriaxone</subject><subject>Ceftriaxone - administration & dosage</subject><subject>Ceftriaxone - therapeutic use</subject><subject>Clarithromycin</subject><subject>Clarithromycin - administration & dosage</subject><subject>Clarithromycin - therapeutic use</subject><subject>Cohort Studies</subject><subject>Community-Acquired Infections - drug therapy</subject><subject>Community-Acquired Infections - microbiology</subject><subject>Community-Acquired Infections - mortality</subject><subject>Community-acquired pneumonia</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Hospitalization</subject><subject>Humans</subject><subject>Levofloxacin</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mortality</subject><subject>Ofloxacin - administration & dosage</subject><subject>Ofloxacin - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Pneumonia, Bacterial - drug therapy</subject><subject>Pneumonia, Bacterial - microbiology</subject><subject>Pneumonia, Bacterial - mortality</subject><subject>Prospective Studies</subject><subject>Treatment Outcome</subject><issn>0924-8579</issn><issn>1872-7913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqN0c2KFDEQB_BGFHdcfQWJB711m_RH0jnK4BcMeNl7qE5XdjJ0J7NJetzxEXxq08zAelMIBIpfVUL9i-IdoxWjjH88VPYALtnZarivakrbioqKsuZZsWG9qEshWfO82FBZt2XfCXlTvIrxQCnrmrZ7Wdywjte0b-im-L3DkzeTfwRtHTlhiEskGk0KFh69Q3Kc1sIEwaZ98PN5ZfmkPZIUENKMLhFvCIzLlCL5mRnRfp4XZ9O5BP2w2IAjOTpcZu8skIBrybp7svfxaBNM9hck693r4oWBKeKb631b3H35fLf9Vu5-fP2-_bQrddvwVCIMY91yYahuJQXWIEqKpjUaB8nBCG7EoHXdjfVQj72GkfV1x9kIA0Pom9viw2XsMfiHBWNSs40apwkc-iUqLppWtoL_EzIhZJcnZygvUAcfY0CjjsHOEM6KUbUGpg7qr8DUGpiiQuXAcu_b6yPLMOP41HlNKIP3VwBRw2QCOG3jk-ON6CUV2W0vDvPqThaDitqi0zjm_eukRm__4zt_AHSUwH0</recordid><startdate>2005</startdate><enddate>2005</enddate><creator>Querol-Ribelles, José Manuel</creator><creator>Tenías, José María</creator><creator>Querol-Borrás, José Manuel</creator><creator>Labrador, Teodoro</creator><creator>Nieto, Angel</creator><creator>González-Granda, Damiana</creator><creator>Martínez, Isidoro</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>C1K</scope><scope>7X8</scope></search><sort><creationdate>2005</creationdate><title>Levofloxacin versus ceftriaxone plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring hospitalization</title><author>Querol-Ribelles, José Manuel ; Tenías, José María ; Querol-Borrás, José Manuel ; Labrador, Teodoro ; Nieto, Angel ; González-Granda, Damiana ; Martínez, Isidoro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c436t-eabd2467f0c490a13ee90ef4fceb96af76f7bcc25d2b2d8cad182561dab1ea83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Aged</topic><topic>Anti-Bacterial Agents - administration & dosage</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Biological and medical sciences</topic><topic>Ceftriaxone</topic><topic>Ceftriaxone - administration & dosage</topic><topic>Ceftriaxone - therapeutic use</topic><topic>Clarithromycin</topic><topic>Clarithromycin - administration & dosage</topic><topic>Clarithromycin - therapeutic use</topic><topic>Cohort Studies</topic><topic>Community-Acquired Infections - drug therapy</topic><topic>Community-Acquired Infections - microbiology</topic><topic>Community-Acquired Infections - mortality</topic><topic>Community-acquired pneumonia</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Hospitalization</topic><topic>Humans</topic><topic>Levofloxacin</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mortality</topic><topic>Ofloxacin - administration & dosage</topic><topic>Ofloxacin - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Pneumonia, Bacterial - drug therapy</topic><topic>Pneumonia, Bacterial - microbiology</topic><topic>Pneumonia, Bacterial - mortality</topic><topic>Prospective Studies</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Querol-Ribelles, José Manuel</creatorcontrib><creatorcontrib>Tenías, José María</creatorcontrib><creatorcontrib>Querol-Borrás, José Manuel</creatorcontrib><creatorcontrib>Labrador, Teodoro</creatorcontrib><creatorcontrib>Nieto, Angel</creatorcontrib><creatorcontrib>González-Granda, Damiana</creatorcontrib><creatorcontrib>Martínez, Isidoro</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of antimicrobial agents</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Querol-Ribelles, José Manuel</au><au>Tenías, José María</au><au>Querol-Borrás, José Manuel</au><au>Labrador, Teodoro</au><au>Nieto, Angel</au><au>González-Granda, Damiana</au><au>Martínez, Isidoro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Levofloxacin versus ceftriaxone plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring hospitalization</atitle><jtitle>International journal of antimicrobial agents</jtitle><addtitle>Int J Antimicrob Agents</addtitle><date>2005</date><risdate>2005</risdate><volume>25</volume><issue>1</issue><spage>75</spage><epage>83</epage><pages>75-83</pages><issn>0924-8579</issn><eissn>1872-7913</eissn><abstract>Consecutive adult patients admitted to the hospital with community-acquired pneumonia from January 2000 to September 2003 were included in this prospective observational cohort study. A total of 459 patients, 259 treated with levofloxacin in single drug therapy at a dose of 500
mg once a day and 209 with the combination of ceftriaxone plus clarithromycin at a dose of 2
g once a day and 500
mg every 12
h, respectively, were included. The hospital admission decision was made using a clinical guideline based on the Pneumonia Severity Index (PSI). Fifteen (6%) patients died in the group treated with levofloxacin in single drug therapy and 25 (12%) in the group treated with ceftriaxone plus clarithromycin (
P = 0.024). The mortality differences between both treatment groups, adjusted by the PSI score, show an OR of 0.39 (95% CI 0.17–0.87). There were no statistically significant differences between the duration of treatments or hospital stay. These data suggest that levofloxacin as single drug therapy is more effective than the combination of ceftriaxone plus clarithromycin in the treatment of moderate to severe pneumonia that requires hospitalization.</abstract><cop>London</cop><cop>Amsterdam</cop><cop>New York, NY</cop><pub>Elsevier B.V</pub><pmid>15620830</pmid><doi>10.1016/j.ijantimicag.2004.07.013</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0924-8579 |
| ispartof | International journal of antimicrobial agents, 2005, Vol.25 (1), p.75-83 |
| issn | 0924-8579 1872-7913 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67349476 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Aged Anti-Bacterial Agents - administration & dosage Anti-Bacterial Agents - therapeutic use Antibiotics. Antiinfectious agents. Antiparasitic agents Biological and medical sciences Ceftriaxone Ceftriaxone - administration & dosage Ceftriaxone - therapeutic use Clarithromycin Clarithromycin - administration & dosage Clarithromycin - therapeutic use Cohort Studies Community-Acquired Infections - drug therapy Community-Acquired Infections - microbiology Community-Acquired Infections - mortality Community-acquired pneumonia Drug Therapy, Combination Female Hospitalization Humans Levofloxacin Male Medical sciences Mortality Ofloxacin - administration & dosage Ofloxacin - therapeutic use Pharmacology. Drug treatments Pneumonia, Bacterial - drug therapy Pneumonia, Bacterial - microbiology Pneumonia, Bacterial - mortality Prospective Studies Treatment Outcome |
| title | Levofloxacin versus ceftriaxone plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring hospitalization |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T14%3A23%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Levofloxacin%20versus%20ceftriaxone%20plus%20clarithromycin%20in%20the%20treatment%20of%20adults%20with%20community-acquired%20pneumonia%20requiring%20hospitalization&rft.jtitle=International%20journal%20of%20antimicrobial%20agents&rft.au=Querol-Ribelles,%20Jos%C3%A9%20Manuel&rft.date=2005&rft.volume=25&rft.issue=1&rft.spage=75&rft.epage=83&rft.pages=75-83&rft.issn=0924-8579&rft.eissn=1872-7913&rft_id=info:doi/10.1016/j.ijantimicag.2004.07.013&rft_dat=%3Cproquest_cross%3E67349476%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17795256&rft_id=info:pmid/15620830&rft_els_id=S0924857904003061&rfr_iscdi=true |